Skip to main content
Caplight Logo









ImmuneBridge

ImmuneBridge

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://immunebridge.com/

Last Round

Seed

Mar 23, 2026

Total Funding Raised

$19.7M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

ImmuneBridge is a biotechnology company developing allogeneic cellular immunotherapies that enhance the body's healing capabilities by expanding cord blood-derived immune stem cells to create a reliable and versatile source for cancer treatments.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

stem cell therapycell-based therapiesregenerative medicineallogeneic cell therapydonor screeningstem cell preservationbiotech platformcell therapy manufacturingdrug discoverymachine learning in biotechoff-the-shelf cell therapysmall moleculecell therapy biotechbiotech R&DGMPgood manufacturing practice

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmuneBridge Comparables

Compare ImmuneBridge with similar companies based on industry and business-model similarity.

ImmuneBridge comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ONK Therapeutics
68%
NK:IO
66%
Garuda Therapeutics
63%

ImmuneBridge Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 23, 2026
SeedApr 10, 2023

ImmuneBridge Investors

Notable investors and investment history

ImmuneBridge investors
InvestorRounds
LongGame VenturesSeed
NFXSeed
One Way VenturesSeed
GaingelsSeed
M VenturesSeed
T.Rx CapitalSeed
Healthspan CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 59% MoM, reaching 2K.

  • Jul 29, 2026

    Grew 19% QoQ, from 16 to 19 employees.

ImmuneBridge Filings

Explore SEC and related filing metadata, where available.

ImmuneBridge filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ImmuneBridge's valuation, stock price, and market status.

Is ImmuneBridge a public or private company?

ImmuneBridge is a private company.

What is the current stock price of ImmuneBridge?

ImmuneBridge is a private company with no public stock price. No recent secondary market data is available.

How much is ImmuneBridge worth (valuation)?

Valuation information for ImmuneBridge is not publicly available.

Can I buy ImmuneBridge stock?

ImmuneBridge shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ImmuneBridge's last funding round?

ImmuneBridge's most recent funding round was Seed on March 24, 2026.

Who are the main investors in ImmuneBridge?

Key investors in ImmuneBridge include NFX, M Ventures, Insight Partners.

Will ImmuneBridge IPO soon?

No public IPO plans have been announced for ImmuneBridge.

How can I track ImmuneBridge secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ImmuneBridge's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range16
Year Founded2018
Last FundingMar 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?